Lunit
Founded Year
2013Stage
Series D | AliveTotal Raised
$135.87MLast Raised
$61M | 7 mos agoAbout Lunit
Lunit is a medical AI software company devoted to providing AI solutions for cancer diagnostics and therapeutics. With its deep learning technology, Lunit makes data-driven medicine the new standard of care. Lunit AI solutions help discover cancer and predict cancer treatment response by finding the right diagnosis at the right costs and the right treatment for the right patients.
Lunit Headquarter Location
15F, 27, Teheran-ro 2-gil Gangnam-gu
Seoul, 06241,
South Korea
Lunit's Product Videos

ESPs containing Lunit
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
Computer-aided diagnostic imaging utilizes algorithms to detect, extract, and communicate data from medical images more efficiently and accurately than the human eye. The technology is being deployed across several imaging modalities to improve the detection, diagnosis, triaging, and, ultimately, the prognosis of various medical conditions.
Lunit named as Leader among 15 other companies, including PathAI, Ibex Medical Analytics, and Aidoc Medical.
Lunit's Products & Differentiation
See Lunit's products and how their products differentiate from alternatives and competitors
Lunit INSIGHT CXR
Analyzes chest x-ray images; identifies 10 abnormal findings and its location, AI's confidence level; triage cases according to urgency
Differentiation
FDA cleared (triage); successful in early commercialization; used in over 40 countries and 400 sites around the world; partnership with major leaders in healthcare such as GE Healthcare, Fujifilm, P…
Subscribe to see more
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Differentiation
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Subscribe to see more
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Differentiation
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Subscribe to see more
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Differentiation
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Subscribe to see more
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Differentiation
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Research containing Lunit
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Lunit in 5 CB Insights research briefs, most recently on Aug 13, 2021.
Expert Collections containing Lunit
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Lunit is included in 9 Expert Collections, including Digital Health.
Digital Health
13,192 items
Startups recreating how healthcare is delivered
Artificial Intelligence
9,051 items
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Digital Health 150
450 items
2019's cohort of the most promising digital health startups transforming the healthcare industry
Medical Devices
11,634 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Digital Hospital
198 items
Startups recreating how healthcare is delivered
Lunit Patents
Lunit has filed 42 patents.
The 3 most popular patent topics include:
- Machine learning
- Artificial neural networks
- Artificial intelligence
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
11/1/2019 | 5/17/2022 | Machine learning, Classification algorithms, Artificial neural networks, Artificial intelligence, Machine learning algorithms | Grant |
Application Date | 11/1/2019 |
---|---|
Grant Date | 5/17/2022 |
Title | |
Related Topics | Machine learning, Classification algorithms, Artificial neural networks, Artificial intelligence, Machine learning algorithms |
Status | Grant |
Latest Lunit News
Jun 21, 2022
Lunit, a leading provider of AI solutions for cancer, has filed a registration statement with the Korean Exchange for an IPO of its common stock. The company intends to list its common stock on the KOSDAQ market. NH Investment & Securities will act as bookrunner. A total of 1,124,300 shares will be offered in the […]
Lunit Web Traffic
Lunit Rank
When was Lunit founded?
Lunit was founded in 2013.
Where is Lunit's headquarters?
Lunit's headquarters is located at 15F, 27, Teheran-ro 2-gil, Seoul.
What is Lunit's latest funding round?
Lunit's latest funding round is Series D.
How much did Lunit raise?
Lunit raised a total of $135.87M.
Who are the investors of Lunit?
Investors of Lunit include Tybourne Capital Management, BrightEdge, NSG Ventures, Casdin Capital, HealthQuest Capital and 18 more.
Who are Lunit's competitors?
Competitors of Lunit include Owkin, Qure.ai, QUIBIM, Ibex Medical Analytics, contextflow, Zebra Medical Vision, ScreenPoint Medical, Paige, PathAI, VUNO and 15 more.
What products does Lunit offer?
Lunit's products include Lunit INSIGHT CXR and 4 more.
Who are Lunit's customers?
Customers of Lunit include Leeds University Hospital, UK.
You May Also Like

Qure.ai has developed an artificial intelligence-based system to identify abnormalities in head CT scans. The company aims to leverage deep learning effectively to diagnose diseases from radiology and pathology imaging and create personalized cancer treatment plans from psychopathology imaging and genome sequences. It was founded in 2016 and is based in Mumbai, India.

Quibim, a company with its headquarters in Valencia, Spain, provides a whole-body medical imaging analysis. Quibim products are used worldwide by a huge diversity of research and care teams. Partners use Quibim Precision, a CE-marked whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers.
Aidoc finds and flags critical findings in medical images. By automatically prioritizing urgent, life-threatening conditions like intracranial hemorrhage and pulmonary embolism, Aidoc saves lives, improves patient care and cuts waiting time for the must urgent patients down to only a few minutes. The always-on AI integrates into a radiologist's workflow, reprioritizing cases without forcing radiologists to change the way they work. Aidoc was founded in 2016 and is based in Tel Aviv, Israel.

MaxQ AI is at the forefront of Medical Diagnostic AI. The company is transforming healthcare by empowering physicians to provide “smarter care” with AI-powered clinical insights. Based in Tel Aviv, Israel and Andover, MA, USA, MaxQ AI developed a software platform that uses AI to interpret medical images and surrounding patient data. Working with world-class clinical and industry partners, the company's software enables caregivers to make faster, more accurate decisions when diagnosing stroke, traumatic brain injury and other serious conditions.

Qritive is developing clinical-grade decision support systems to enhance histopathology diagnosis of cancer and to assist doctors in delivering insightful and personalized care to patients. The company has developed Pantheon, a CE marked vendor-agnostic digital pathology platform that enables digitization of the entire pathology lab workflow and telepathology, supports rich report generation, and provides a platform for AI analysis of pathology whole-slide images.

Owkin specializes in AI technologies applied to clinical research with the aim of developing better drugs and treatments for patients. The company's purpose is to empower researchers in hospitals, universities and the biopharma industry to i) understand why drug efficacy varies from patient to patient, ii) improve the drug development process and iii) to help identify key drugs and treatments for each individual patient to improve patient outcomes. The company's precision medicine platform aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The Owkin platform aims to enable partners to uncover siloed datasets while maintaining patient privacy and securing proprietary data using Federated Learning and innovative collaborative AI technology.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.